作者
Rohan K. Jupelly,Abdul Moeed,Fidel Cai,Sanam Mir Ghazi,Patrick Ruz,Ifeanyichukwu Ozobu,Mussammat Ferdousi,Vlad Gabriel Zaha,Kathleen Zhang,Alvin Chandra,Amit Arbune,Farrukh Tauseef Awan,Narendranath Epperla,Daniel Addison
摘要
Background: Immune checkpoint inhibitors (ICIs) have transformed cancer care but are linked with toxicity. Cases of unexplained arrhythmias have been reported. Yet, the incidence, temporal trajectory, and prognostic implications of arrhythmias with ICIs remain unknown. Methods: Leveraging a large US-based federated network of 54 healthcare organizations, we identified adults with advanced malignancies and no baseline cardiovascular disease who received first-line cancer therapy, with or without a PD-1 or PD-L1 inhibitor, between 2015-2024. The primary outcome was incident arrhythmia. Secondary outcomes included major adverse cardiovascular events (MI, systolic HF, myocarditis, pericarditis, ventricular arrhythmia, cardiac arrest, and high-grade AV block; MACE), the individual MACE components, and all-cause mortality at 90-days, 1-year, and 2-years. Propensity matching, accounting for traditional cardiovascular, oncologic, and treatment-related risk factors was performed. Cox proportional hazards models were used to estimate survival outcomes. Subgroup analyses evaluated the prognostic significance of new-onset arrhythmia and the association of corticosteroids, beta-blockers, and other anti-arrhythmic agents with mortality. Results: Overall, 15,554 propensity-matched patients (7,777 ICI-treated compared to 7,777 chemotherapy-only) were identified. Over a median follow-up of 17 months, ICI-exposure was associated with delayed arrhythmic-risk, absent at 90 days but evident by 1-year (HR 1.10) and progressing through 2-years (HR 1.14); namely atrial fibrillation (HR 1.24) and high-grade atrioventricular blocks (HR 2.65), all P <0.01; Figure 1 . MACE, heart failure, and pericardial-effusion followed similar patterns ( P <0.001). New-onset arrhythmia associated with a 3-fold increase in non-arrhythmia MACE (HR 3.46, P <0.001) and higher mortality (HR 1.16, P =0.001); Figure 2 . No specific cardiovascular drug-class associated with lower subsequent risk of MACE, while early corticosteroid use (HR 0.76, P =0.0003) and angiotensin inhibition (0.64, P <0.0001) associated with lower mortality. Conclusions: Among patients receiving ICI-therapy, new-onset arrhythmia identifies those at elevated-risk for broader cardiovascular events and mortality.